$2M in Federal Funding for PILLAR’s Project Re-entry and Treatment Network

Translate to Spanish or other 102 languages!

Senator Henry Cuellar announced $2,000,000 in federal funding for PILLAR's Project Re-entry and Treatment Network. Courtesy Image
Senator Henry Cuellar announced $2,000,000 in federal funding for PILLAR’s Project Re-entry and Treatment Network. Courtesy Image

Mega Doctor News

- Advertisement -

Senator Henry Cuellar announced $2,000,000 in federal funding for PILLAR’s Project Re-entry and Treatment Network. The funds, awarded by the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA), will be used to provide re-entry services, treatment, and recovery support services for 330 individuals.

PILLAR will utilize the award over a 5-year period to treat incarcerated individuals struggling with substance use disorders and/or co-occurring disorders as they return to their families and community. 50 persons will be treated in Year 1, and 70 persons will be treated each year in Years 2 through 5.

Mental health care is essential to our community’s wellbeing. This $2,000,000 investment will help PILLAR provide the care and treatment needed to get individuals suffering with substance use disorders back on their feet and back into the world. The senator woud like to thank PILLAR Co-Founders Arturo Diaz, Jr., and Manuel Sanchez for working with him to deliver for the community.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.
- Advertisement -